Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)

Életkor

• 1\) Age: patients \> 25 years old at diagnosis 2) Absence of patient or parents or legal representative written informed consent 3) Patient for whom follow-up by the investigating centre does not appear feasible

Egyéb

• Main non-inclusion Criteria common to all study cohorts:

• Inclusion within 3 months after diagnosis
• Availability of a cryopreserved tumour sample (primary and/or metastatic and/or lymph nodes) or peripheral blood or bone marrow samples (if invasion more than 30% of lymphoblasts) for leukaemias, obtained at the time of diagnosis during a routine procedure
• Availability of a formalin-fixed paraffin-embedded (FFPE) tumour sample (primary and/or metastasis and/or lymph nodes), obtained at the time of diagnosis during a routine procedure (except for leukaemia patients)
• Age: ≤ 25 years at diagnosis
• Written patient informed consent, or parents or legal representative written informed consent and assent of the child and the adolescent
• Compulsory affiliation to a social security scheme
  • Additional inclusion criteria for the study:
  • To avoid multiple sampling for children, adolescents and young adults with cancer, patients already included or to be included in a study with similar analyses and/or objectives might also be included in MICCHADO study and in this case, samples or data might be exchanged on a collaborative basis.
  • Cohort 1:
  • High risk neuroblastoma:
  • \- Any type of neuroblastoma with MYCN amplification, except INSS stage 1
  • \- Stage 4 neuroblastoma in children older than one year at diagnosis
  • High risk rhabdomyosarcoma:
  • Foxo1 rearrangement any stage;
  • and / or N1 ;
  • and / or metastatic rhabdomyosarcoma
  • High risk Ewing sarcoma:
  • Metastatic Ewing sarcoma family of tumours (ESFT)
  • Localised inoperable Ewing sarcoma with primary tumours ≥ 200 ml
  • High risk osteosarcoma:
  • \- Metastatic osteosarcoma
  • \- Localised inoperable osteosarcoma
  • High risk leukaemia:
  • Secondary acute myeloid leukaemia
  • Biphenotypic acute leukaemia
  • Cohort 2:
  • Extra cerebral or cerebral high risk tumours including:
  • other metastatic sarcomas,
  • other rare high risk cancers,
  • high risk renal tumours with surgery after an initial chemotherapy
  • rhabdoid brain tumours (AT/RT) and extra cerebral rhabdoid tumours
  • high risk or metastatic cancers of unclear histological diagnosis • Lymphoblastic leukaemia with high MRD at Day 78 (time point 2) • Very high risk T-cells acute lymphoblastic leukaemia:
  • MRD ≥ 10-2 at the end of the induction ;
  • or MRD ≥ 10-3 at Day 78
  • Cohort 3:
  • Children, adolescents and young adults, with low/intermediate risk cancers belonging to the following types:
  • Neuroblastoma:
  • \- Localised, without MYCN amplification
  • Localised, INSS stage 1, with MYCN amplification
  • Stage 4s, in infants (younger than one year at diagnosis), without MYCN amplification
  • Rhabdomyosarcoma:
  • Localised, without Foxo1 rearrangement
  • ESFT:
  • All non-high risk localised ESFT • Osteosarcoma:
  • All non-high risk localised osteosarcoma